A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

Inclusion Criteria

• •Male or female of any race, 18 to 65 (inclusive) years of age.
• •Freely given verbal and written informed consent obtained from the subject.
• •Clinical diagnosis of psoriasis at the Screening and Baseline visits with
• •At least 10% - 20% of total treatable BSA involvement, and
• •an Investigator's Global Evaluation score of 3 or 4 ( moderate or severe) on a scale of 0 to 5
• •Good general health as determined by the Investigator based on the subject's medical history and physical examination, with Screening hematology, serum chemistry, and urinalysis laboratory values within normal range limits.